KIT and acute myeloid leukemia: It is also noteworthy that, in sharp contrast to imatinib or crizotinib that induce cytoprotective autophagy, midostaurin (PKC412), a pan-tyrosine-kinase inhibitor that potently targets KIT, decreased autophagy flux in KIT-mutated AML cells10,39.